dulaglutide vs Semaglutide (Ozempic)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

dulaglutide · Trulicity

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01394952 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).

Next expected readout: April 2027 · NCT07537088 (registry estimate)

Reported efficacy

Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04) (met)

Result source: NCT03495102

Semaglutide (Ozempic)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01720446 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (From Week 0 up to Week 234): Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. (met)

Result source: NCT03819153

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdulaglutideSemaglutide (Ozempic)
HbA1c, change-2.0% vs -1.1%−0.9 vs placebo1.5 mg · wk 28 · n 133NCT04591626
25 other results
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 132 · Phase 3 · primary NCT02597049
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 130 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 134 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 131 · Phase 3 · primary NCT02597049
  • -1.4% vs -0.7% wk 28 · n 150 · Phase 3 · primary NCT02152371
  • -1.4% vs -0.1% wk 24 · n 215 · Phase 3 · primary NCT01769378
  • -1.2% vs -1.1% 1.5 mg · wk 26 · n 138 · Phase 3 · primary NCT01621178
  • -1.7% vs -1.2% 1.5 mg · wk 26 · n 253 · Phase 3 · primary NCT01648582
  • -1.5% vs -0.9% 1.5 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -1.4% 1.5 mg weekly · wk 26 · n 279 · Phase 3 · primary NCT01624259
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.3% vs -1.2% 0.75 mg · wk 26 · n 252 · Phase 3 · primary NCT01648582
  • -1.2% vs -0.9% 0.75 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -0.9% wk 26 · n 178 · Phase 3 · primary NCT01584232
  • -1% vs 0.5% 1.5 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.5% vs 0.5% 0.75 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.9% vs -1.7% 1.5 mg · wk 156 · n 6579 · Phase 3 · secondary NCT04255433
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.5% vs -0.9% 1.5 mg · wk 52 · n 253 · Phase 3 · secondary NCT01648582
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.0% vs -0.9% 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.4% vs -0.4% 4.5 mg · wk 18 · n 66 · Phase 2 · primary NCT02973100
  • -1.3% vs -0.4% 3.0 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.2% vs -0.4% 1.5 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.4% vs 0.1% wk 16 · n 120 · Phase 4 · primary NCT02750410
-1.6% vs 0%−1.6 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
35 other results
  • -1.9% vs -0.1% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.2% 1.0 mg weekly · wk 30 · n 151 · Phase 3 · primary NCT03086330
  • -1.5% vs 0% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · primary NCT02054897
  • -1.4% vs -0.1% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · primary NCT02305381
  • -1.5% vs -0.9% 1.0 mg · wk 56 · n 404 · Phase 3 · primary NCT01885208
  • -1.6% vs -0.6% 1.0 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.8% vs -1.1% 1.0 mg · wk 40 · n 300 · Phase 3 · primary NCT02648204
  • -1.6% vs -0.8% 1.0 mg/week · wk 30 · n 360 · Phase 3 · primary NCT02128932
  • -1.7% vs -1.1% 1.0 mg · wk 30 · n 290 · Phase 3 · primary NCT03191396
  • -1.3% vs -0.6% 0.5 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.5% vs -1.1% 0.5 mg · wk 40 · n 301 · Phase 3 · primary NCT02648204
  • -1.2% vs -0.8% 0.5 mg/week · wk 30 · n 362 · Phase 3 · primary NCT02128932
  • -1.5% vs -1.2% wk 52 · n 795 · Phase 3 · primary NCT03689374
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · primary NCT05514535
  • -1.4% vs -0.4% 1.0 mg · wk 104 · n 822 · Phase 3 · secondary NCT01720446
  • -1.1% vs -0.4% 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -0.9% vs -0.0% wk 104 · n 1448 · Phase 3 · secondary NCT03819153
  • -1.8% vs -0.3% 7.2 mg · wk 72 · n 288 · Phase 3 · secondary NCT05649137
  • -0.8% vs 0.2% wk 52 · n 304 · Phase 3 · secondary NCT04560998
  • -2.0% vs -0.7% 1.0 mg · wk 56 · n 204 · Phase 3 · secondary NCT02207374
  • -2.2% vs -0.7% 1.0 mg · wk 30 · n 102 · Phase 3 · secondary NCT02254291
  • -1.7% vs -0.7% 0.5 mg · wk 56 · n 220 · Phase 3 · secondary NCT02207374
  • -1.9% vs -0.7% 0.5 mg · wk 30 · n 103 · Phase 3 · secondary NCT02254291
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · secondary NCT05514535
  • -1.9% vs -1.1% 2.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.1% vs -0.4% 21.6 mg · wk 34 · n 59 · Phase 2 · primary NCT05144984
  • -2.1% vs -1.1% 16.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.8% vs -1.1% 8.0 mg · wk 40 · n 57 · Phase 2 · primary NCT05486065
  • -2.3% vs -0.4% 2.4 mg + 2.4 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 7.2 mg · wk 34 · n 74 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 12.0 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.3% vs -0.4% 2.4 mg + 21.6 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • -1.5% vs -1.1% wk 52 · n 430 · Phase 4 · secondary NCT03596450
  • -1.4% vs -1.0% wk 104 · n 374 · Phase 4 · secondary NCT03596450
Body weight, change (kg)-0.8 vs 0.4−1.2 vs placebo1.5 mg · wk 28 · n 133NCT04591626
18 other results
  • -1.9 vs 0.5 wk 28 · n 150 · Phase 3 · secondary NCT02152371
  • -0.9 vs -0.2 wk 24 · n 212 · Phase 3 · secondary NCT01769378
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.1 vs 1.4 1.5 mg · wk 52 · n 258 · Phase 3 · secondary NCT01648582
  • -2.8 vs 1.1 1.5 mg · wk 26 · n 140 · Phase 3 · secondary NCT01621178
  • -1.5 vs 1.0 1.5 mg · wk 26 · n 258 · Phase 3 · secondary NCT01648582
  • -1.5 vs 0.9 1.5 mg · wk 26 · n 222 · Phase 3 · secondary NCT01644500
  • -2.9 vs -3.6 1.5 mg weekly · wk 26 · n 299 · Phase 3 · secondary NCT01624259
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -0.8 vs 1.4 0.75 mg · wk 52 · n 257 · Phase 3 · secondary NCT01648582
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -0.9 vs 1.0 0.75 mg · wk 26 · n 257 · Phase 3 · secondary NCT01648582
  • -0.8 vs 0.9 0.75 mg · wk 26 · n 224 · Phase 3 · secondary NCT01644500
  • -0.5 vs 0.9 wk 26 · n 180 · Phase 3 · secondary NCT01584232
  • -4.1 vs -1.6 4.5 mg · wk 18 · n 67 · Phase 2 · secondary NCT02973100
  • -3.9 vs -1.6 3.0 mg · wk 18 · n 74 · Phase 2 · secondary NCT02973100
  • -2.8 vs -1.6 1.5 mg · wk 18 · n 72 · Phase 2 · secondary NCT02973100
  • -0.2 vs -0.3 wk 16 · n 120 · Phase 4 · secondary NCT02750410
-4.9 vs -0.6−4.3 vs placebo1.0 mg · wk 104 · n 822NCT01720446
32 other results
  • -3.6 vs -0.6 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -5.5 vs -1.4 wk 104 · n 1502 · Phase 3 · secondary NCT03819153
  • -4.7 vs -0.9 1.0 mg weekly · wk 30 · n 130 · Phase 3 · secondary NCT02054897
  • -6.4 vs -1.4 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -4.7 vs -1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -3.7 vs -0.9 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • -3.7 vs -1.4 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -14.9 vs -4.6 7.2 mg · wk 72 · n 291 · Phase 3 · secondary NCT05649137
  • -5.2 vs -1.2 wk 52 · n 310 · Phase 3 · secondary NCT04560998
  • -5.6 vs -1.9 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -6.1 vs -1.9 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -6.5 vs -2.3 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • -5.2 vs 1.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -5.8 vs -2 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -4.3 vs -1.9 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -3.5 vs 1.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -4.2 vs 2.9 wk 52 · n 801 · Phase 3 · secondary NCT03689374
  • -4.2 vs -0.4 1.0 mg weekly · wk 30 · n 239 · Phase 3 · secondary NCT03061214
  • -4.6 vs -2.3 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • -3 vs -0.4 0.5 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -5.7 vs -4.3 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -8.0 vs 0.4 wk 40 · n 282 · Phase 3 · secondary NCT05514535
  • -8.9 vs -2.3 2.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -4.7 vs -2.6 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -13.1 vs -2.3 16.0 mg · wk 40 · n 55 · Phase 2 · secondary NCT05486065
  • -10.1 vs -2.3 8.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -8.9 vs -2.6 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 7.2 mg · wk 34 · n 60 · Phase 2 · secondary NCT05144984
  • -10 vs -2.6 2.4 mg + 12.0 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 21.6 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -5 vs -3.1 wk 104 · n 389 · Phase 4 · secondary NCT03596450
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
HbA1c below 7%75.9% vs 33.8%+42.1 vs placebo1.5 mg · wk 28 · n 133NCT04591626
8 other results
  • 32.9% vs 29.1% 1.5 mg · wk 52 · n 152 · Phase 3 · secondary NCT01621178
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
  • 68.2% vs 20% 4.5 mg · wk 18 · n 66 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 3.0 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 1.5 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 0% vs 47.4% wk 16 · n 116 · Phase 4 · secondary NCT02750410
72.3% vs 24.8%+47.5 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
10 other results
  • 78.6% vs 10.5% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • 82.5% vs 20.5% 1.0 mg weekly · wk 30 · n 120 · Phase 3 · secondary NCT03086330
  • 74.2% vs 24.8% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • 60.6% vs 10.5% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • 78.7% vs 52.2% 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • 84% vs 49.6% 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • 80.4% vs 45.9% 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • 68.4% vs 52.2% 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • 74.5% vs 49.6% 0.5 mg weekly · wk 30 · n 235 · Phase 3 · secondary NCT03061214
  • 76.1% vs 50.8% wk 52 · n 293 · Phase 3 · secondary NCT03136484
Fasting plasma glucose, change-2.2 vs -2.4vs Insulin Glargine1.5 mg · wk 52 · n 253NCT01648582
3 other results
  • -2.4 vs -2.6 1.5 mg · wk 26 · n 253 · Phase 3 · secondary NCT01648582
  • -1.5 vs -2.4 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.7 vs -2.6 0.75 mg · wk 26 · n 252 · Phase 3 · secondary NCT01648582
-2.1 vs -0.9−1.2 vs placebo1.0 mg · wk 104 · n 822NCT01720446
24 other results
  • -1.8 vs -0.9 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -2.4 vs -0.6 1.0 mg weekly · wk 30 · n 129 · Phase 3 · secondary NCT02054897
  • -2.4 vs -0.5 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -2.3 vs 0.1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -2.4 vs -0.6 0.5 mg weekly · wk 30 · n 125 · Phase 3 · secondary NCT02054897
  • -1.6 vs -0.5 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -3.3 vs -1.1 7.2 mg · wk 72 · n 281 · Phase 3 · secondary NCT05649137
  • -2.8 vs -2 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -2.6 vs -1.1 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.8 vs -1.9 1.0 mg · wk 40 · n 299 · Phase 3 · secondary NCT02648204
  • -2.7 vs -2.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -2.6 vs -1 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -2.6 vs -1.5 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -2.1 vs -1.1 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.2 vs -1.9 0.5 mg · wk 40 · n 298 · Phase 3 · secondary NCT02648204
  • -2.0 vs -2.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -1.3 vs -0.8 wk 52 · n 770 · Phase 3 · secondary NCT03689374
  • -2.2 vs -1 0.5 mg weekly · wk 30 · n 237 · Phase 3 · secondary NCT03061214
  • -2.5 vs -2 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -1.4 vs -0.1 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -3.9 vs -0.1 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -3.4 vs -0.1 2.4 mg + 7.2 mg · wk 34 · n 58 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 12.0 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 21.6 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
3-point MACE (% with event)12% vs 13.4%−1.4 vs placebon 4949NCT01394952
1 other result
  • 13.1% vs 12.2% 1.5 mg · wk 259 · n 6579 · Phase 3 · primary NCT04255433
6.6% vs 8.9%−2.3 vs placebon 1648NCT01720446
1 other result
  • 12% vs 14.4% n 1767 · Phase 3 · secondary NCT03819153

HbA1c, change

dulaglutide
-2.0% vs -1.1%−0.9 vs placebo1.5 mg · wk 28 · n 133NCT04591626
25 other results
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 132 · Phase 3 · primary NCT02597049
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 130 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 134 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 131 · Phase 3 · primary NCT02597049
  • -1.4% vs -0.7% wk 28 · n 150 · Phase 3 · primary NCT02152371
  • -1.4% vs -0.1% wk 24 · n 215 · Phase 3 · primary NCT01769378
  • -1.2% vs -1.1% 1.5 mg · wk 26 · n 138 · Phase 3 · primary NCT01621178
  • -1.7% vs -1.2% 1.5 mg · wk 26 · n 253 · Phase 3 · primary NCT01648582
  • -1.5% vs -0.9% 1.5 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -1.4% 1.5 mg weekly · wk 26 · n 279 · Phase 3 · primary NCT01624259
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.3% vs -1.2% 0.75 mg · wk 26 · n 252 · Phase 3 · primary NCT01648582
  • -1.2% vs -0.9% 0.75 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -0.9% wk 26 · n 178 · Phase 3 · primary NCT01584232
  • -1% vs 0.5% 1.5 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.5% vs 0.5% 0.75 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.9% vs -1.7% 1.5 mg · wk 156 · n 6579 · Phase 3 · secondary NCT04255433
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.5% vs -0.9% 1.5 mg · wk 52 · n 253 · Phase 3 · secondary NCT01648582
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.0% vs -0.9% 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.4% vs -0.4% 4.5 mg · wk 18 · n 66 · Phase 2 · primary NCT02973100
  • -1.3% vs -0.4% 3.0 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.2% vs -0.4% 1.5 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.4% vs 0.1% wk 16 · n 120 · Phase 4 · primary NCT02750410
Semaglutide (Ozempic)
-1.6% vs 0%−1.6 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
35 other results
  • -1.9% vs -0.1% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.2% 1.0 mg weekly · wk 30 · n 151 · Phase 3 · primary NCT03086330
  • -1.5% vs 0% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · primary NCT02054897
  • -1.4% vs -0.1% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · primary NCT02305381
  • -1.5% vs -0.9% 1.0 mg · wk 56 · n 404 · Phase 3 · primary NCT01885208
  • -1.6% vs -0.6% 1.0 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.8% vs -1.1% 1.0 mg · wk 40 · n 300 · Phase 3 · primary NCT02648204
  • -1.6% vs -0.8% 1.0 mg/week · wk 30 · n 360 · Phase 3 · primary NCT02128932
  • -1.7% vs -1.1% 1.0 mg · wk 30 · n 290 · Phase 3 · primary NCT03191396
  • -1.3% vs -0.6% 0.5 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.5% vs -1.1% 0.5 mg · wk 40 · n 301 · Phase 3 · primary NCT02648204
  • -1.2% vs -0.8% 0.5 mg/week · wk 30 · n 362 · Phase 3 · primary NCT02128932
  • -1.5% vs -1.2% wk 52 · n 795 · Phase 3 · primary NCT03689374
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · primary NCT05514535
  • -1.4% vs -0.4% 1.0 mg · wk 104 · n 822 · Phase 3 · secondary NCT01720446
  • -1.1% vs -0.4% 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -0.9% vs -0.0% wk 104 · n 1448 · Phase 3 · secondary NCT03819153
  • -1.8% vs -0.3% 7.2 mg · wk 72 · n 288 · Phase 3 · secondary NCT05649137
  • -0.8% vs 0.2% wk 52 · n 304 · Phase 3 · secondary NCT04560998
  • -2.0% vs -0.7% 1.0 mg · wk 56 · n 204 · Phase 3 · secondary NCT02207374
  • -2.2% vs -0.7% 1.0 mg · wk 30 · n 102 · Phase 3 · secondary NCT02254291
  • -1.7% vs -0.7% 0.5 mg · wk 56 · n 220 · Phase 3 · secondary NCT02207374
  • -1.9% vs -0.7% 0.5 mg · wk 30 · n 103 · Phase 3 · secondary NCT02254291
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · secondary NCT05514535
  • -1.9% vs -1.1% 2.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.1% vs -0.4% 21.6 mg · wk 34 · n 59 · Phase 2 · primary NCT05144984
  • -2.1% vs -1.1% 16.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.8% vs -1.1% 8.0 mg · wk 40 · n 57 · Phase 2 · primary NCT05486065
  • -2.3% vs -0.4% 2.4 mg + 2.4 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 7.2 mg · wk 34 · n 74 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 12.0 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.3% vs -0.4% 2.4 mg + 21.6 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • -1.5% vs -1.1% wk 52 · n 430 · Phase 4 · secondary NCT03596450
  • -1.4% vs -1.0% wk 104 · n 374 · Phase 4 · secondary NCT03596450

Body weight, change (kg)

dulaglutide
-0.8 vs 0.4−1.2 vs placebo1.5 mg · wk 28 · n 133NCT04591626
18 other results
  • -1.9 vs 0.5 wk 28 · n 150 · Phase 3 · secondary NCT02152371
  • -0.9 vs -0.2 wk 24 · n 212 · Phase 3 · secondary NCT01769378
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.1 vs 1.4 1.5 mg · wk 52 · n 258 · Phase 3 · secondary NCT01648582
  • -2.8 vs 1.1 1.5 mg · wk 26 · n 140 · Phase 3 · secondary NCT01621178
  • -1.5 vs 1.0 1.5 mg · wk 26 · n 258 · Phase 3 · secondary NCT01648582
  • -1.5 vs 0.9 1.5 mg · wk 26 · n 222 · Phase 3 · secondary NCT01644500
  • -2.9 vs -3.6 1.5 mg weekly · wk 26 · n 299 · Phase 3 · secondary NCT01624259
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -0.8 vs 1.4 0.75 mg · wk 52 · n 257 · Phase 3 · secondary NCT01648582
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -0.9 vs 1.0 0.75 mg · wk 26 · n 257 · Phase 3 · secondary NCT01648582
  • -0.8 vs 0.9 0.75 mg · wk 26 · n 224 · Phase 3 · secondary NCT01644500
  • -0.5 vs 0.9 wk 26 · n 180 · Phase 3 · secondary NCT01584232
  • -4.1 vs -1.6 4.5 mg · wk 18 · n 67 · Phase 2 · secondary NCT02973100
  • -3.9 vs -1.6 3.0 mg · wk 18 · n 74 · Phase 2 · secondary NCT02973100
  • -2.8 vs -1.6 1.5 mg · wk 18 · n 72 · Phase 2 · secondary NCT02973100
  • -0.2 vs -0.3 wk 16 · n 120 · Phase 4 · secondary NCT02750410
Semaglutide (Ozempic)
-4.9 vs -0.6−4.3 vs placebo1.0 mg · wk 104 · n 822NCT01720446
32 other results
  • -3.6 vs -0.6 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -5.5 vs -1.4 wk 104 · n 1502 · Phase 3 · secondary NCT03819153
  • -4.7 vs -0.9 1.0 mg weekly · wk 30 · n 130 · Phase 3 · secondary NCT02054897
  • -6.4 vs -1.4 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -4.7 vs -1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -3.7 vs -0.9 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • -3.7 vs -1.4 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -14.9 vs -4.6 7.2 mg · wk 72 · n 291 · Phase 3 · secondary NCT05649137
  • -5.2 vs -1.2 wk 52 · n 310 · Phase 3 · secondary NCT04560998
  • -5.6 vs -1.9 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -6.1 vs -1.9 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -6.5 vs -2.3 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • -5.2 vs 1.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -5.8 vs -2 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -4.3 vs -1.9 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -3.5 vs 1.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -4.2 vs 2.9 wk 52 · n 801 · Phase 3 · secondary NCT03689374
  • -4.2 vs -0.4 1.0 mg weekly · wk 30 · n 239 · Phase 3 · secondary NCT03061214
  • -4.6 vs -2.3 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • -3 vs -0.4 0.5 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -5.7 vs -4.3 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -8.0 vs 0.4 wk 40 · n 282 · Phase 3 · secondary NCT05514535
  • -8.9 vs -2.3 2.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -4.7 vs -2.6 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -13.1 vs -2.3 16.0 mg · wk 40 · n 55 · Phase 2 · secondary NCT05486065
  • -10.1 vs -2.3 8.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -8.9 vs -2.6 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 7.2 mg · wk 34 · n 60 · Phase 2 · secondary NCT05144984
  • -10 vs -2.6 2.4 mg + 12.0 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 21.6 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -5 vs -3.1 wk 104 · n 389 · Phase 4 · secondary NCT03596450
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352

HbA1c below 7%

dulaglutide
75.9% vs 33.8%+42.1 vs placebo1.5 mg · wk 28 · n 133NCT04591626
8 other results
  • 32.9% vs 29.1% 1.5 mg · wk 52 · n 152 · Phase 3 · secondary NCT01621178
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
  • 68.2% vs 20% 4.5 mg · wk 18 · n 66 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 3.0 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 1.5 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 0% vs 47.4% wk 16 · n 116 · Phase 4 · secondary NCT02750410
Semaglutide (Ozempic)
72.3% vs 24.8%+47.5 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
10 other results
  • 78.6% vs 10.5% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • 82.5% vs 20.5% 1.0 mg weekly · wk 30 · n 120 · Phase 3 · secondary NCT03086330
  • 74.2% vs 24.8% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • 60.6% vs 10.5% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • 78.7% vs 52.2% 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • 84% vs 49.6% 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • 80.4% vs 45.9% 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • 68.4% vs 52.2% 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • 74.5% vs 49.6% 0.5 mg weekly · wk 30 · n 235 · Phase 3 · secondary NCT03061214
  • 76.1% vs 50.8% wk 52 · n 293 · Phase 3 · secondary NCT03136484

Fasting plasma glucose, change

dulaglutide
-2.2 vs -2.4vs Insulin Glargine1.5 mg · wk 52 · n 253NCT01648582
3 other results
  • -2.4 vs -2.6 1.5 mg · wk 26 · n 253 · Phase 3 · secondary NCT01648582
  • -1.5 vs -2.4 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.7 vs -2.6 0.75 mg · wk 26 · n 252 · Phase 3 · secondary NCT01648582
Semaglutide (Ozempic)
-2.1 vs -0.9−1.2 vs placebo1.0 mg · wk 104 · n 822NCT01720446
24 other results
  • -1.8 vs -0.9 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -2.4 vs -0.6 1.0 mg weekly · wk 30 · n 129 · Phase 3 · secondary NCT02054897
  • -2.4 vs -0.5 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -2.3 vs 0.1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -2.4 vs -0.6 0.5 mg weekly · wk 30 · n 125 · Phase 3 · secondary NCT02054897
  • -1.6 vs -0.5 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -3.3 vs -1.1 7.2 mg · wk 72 · n 281 · Phase 3 · secondary NCT05649137
  • -2.8 vs -2 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -2.6 vs -1.1 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.8 vs -1.9 1.0 mg · wk 40 · n 299 · Phase 3 · secondary NCT02648204
  • -2.7 vs -2.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -2.6 vs -1 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -2.6 vs -1.5 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -2.1 vs -1.1 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.2 vs -1.9 0.5 mg · wk 40 · n 298 · Phase 3 · secondary NCT02648204
  • -2.0 vs -2.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -1.3 vs -0.8 wk 52 · n 770 · Phase 3 · secondary NCT03689374
  • -2.2 vs -1 0.5 mg weekly · wk 30 · n 237 · Phase 3 · secondary NCT03061214
  • -2.5 vs -2 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -1.4 vs -0.1 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -3.9 vs -0.1 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -3.4 vs -0.1 2.4 mg + 7.2 mg · wk 34 · n 58 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 12.0 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 21.6 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984

3-point MACE (% with event)

dulaglutide
12% vs 13.4%−1.4 vs placebon 4949NCT01394952
1 other result
  • 13.1% vs 12.2% 1.5 mg · wk 259 · n 6579 · Phase 3 · primary NCT04255433
Semaglutide (Ozempic)
6.6% vs 8.9%−2.3 vs placebon 1648NCT01720446
1 other result
  • 12% vs 14.4% n 1767 · Phase 3 · secondary NCT03819153
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. dulaglutide: 10 of 10 rows · Semaglutide (Ozempic): 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdulaglutide
Rows use multiple source trials
Semaglutide (Ozempic)
Rows use multiple source trials
BMI
absolute change · kg
-0.4 vs 0.52 Insulin Glargine kg @ 52wk1.5 mga,b,c
NCT01648582 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.27 vs 0.52 Insulin Glargine kg @ 52wk0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
-1.5 vs 1 Insulin Aspart kg @ 52wkb,c
NCT03689374 · Phase 3 · registry result, not featured evidence
1 other source trial
-2 vs -1.5 Canagliflozin kg @ 52wk
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
HbA1c
absolute change · percentage points
No placebo or comparator arm
-1.5% (n=383) @ 52wk1.5 mga,b,c
NCT04809220 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.19% (n=193) @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-1.23% (n=91) @ 52wkb,c
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
-0.86% (n=335) @ 52wk
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain
responder rate · % of participants
51.8% (n=139) vs 21.1% (n=147) placebo @ 28wk1.5 mgd,b,e,f
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
69.6% (n=293) vs 45% (n=313) Canagliflozin @ 52wkd,b,e,f
Yes
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
HbA1c Less Than 7%
responder rate · % of participants
No placebo or comparator arm
71.48% (n=526) @ 36wk4.5 mga,b,c,g
NCT03495102 · Phase 3
show 2 more doses
64.68% (n=521) @ 36wk3 mg
NCT03495102 · Phase 3
56.98% (n=523) @ 36wk1.5 mg
NCT03495102 · Phase 3
67.6% (n=480) @ 40wk2.0 mg weeklya,b,c,g
NCT03989232 · Phase 3
show 1 more dose
57.5% (n=481) @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
Weight
percent change · % of baseline
-4.82% (n=6578) vs -11.6% (n=6586) Tirzepatide @ 156wk1.5 mgh,b,c,i
NCT04255433 · Phase 3 · registry result, not featured evidence
-4.47% (n=389) vs -2.68% (n=386) Standard of Care @ 104wkh,b,c,i
NCT03596450 · Phase 4 · registry result, not featured evidence
Weight
absolute change · kg
No placebo or comparator arm
-0.5 kg @ 52wk1.5 mga,b,c
NCT04809220 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.2 kg @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-3.85 kg @ 52wkb,c
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
-3.77 kg @ 52wk
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
Dropout rate
0.3%j
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
4.4%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.8%4.5 mg
NCT03495102 · Phase 3
10.9%3 mg
NCT03495102 · Phase 3
9.2%1.5 mg
NCT03495102 · Phase 3
—1.5 mg
NCT01621178 · Phase 3
—0.75 mg
NCT01621178 · Phase 3
3.8%1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
3.9%0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
2.5%Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
—
NCT03315780 · Phase 4 · registry result, not featured evidence
2.2%1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
3.1%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
4.9%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
3.5%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
8%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
12.4%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
14.8%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
10.4%
NCT01769378 · Phase 3 · registry result, not featured evidence
9%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
9.7%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
—1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
10%LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
9.2%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
5.1%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
16.7%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
1.3%1.0 mgk
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
1.7%0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.9%1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.4%
NCT03819153 · Phase 3
5.4%1.0 mg weekly
NCT02054897 · Phase 3
7.8%0.5 mg weekly
NCT02054897 · Phase 3
5.1%1.0 mg weekly
NCT01930188 · Phase 3 · combination
5.4%0.5 mg weekly
NCT01930188 · Phase 3 · combination
5.3%1.0 mg/week
NCT02128932 · Phase 3
7.5%0.5 mg/week
NCT02128932 · Phase 3
3.8%2.0 mg weekly
NCT03989232 · Phase 3
2.1%1.0 mg weekly
NCT03989232 · Phase 3
3.8%1.0 mg weekly
NCT02305381 · Phase 3
3.8%0.5 mg weekly
NCT02305381 · Phase 3
0%
NCT04126603 · Phase 4 · registry result, not featured evidence
0%
NCT05786521 · Phase 4 · registry result, not featured evidence
10.6%
NCT05533632 · Phase 4 · registry result, not featured evidence
0%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
28.1%
NCT03596450 · Phase 4 · registry result, not featured evidence
36.5%Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
1.7%Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
3.9%7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
18.3%1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
7.6%
NCT04560998 · Phase 3 · registry result, not featured evidence
1.5%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
NCT03689374 · Phase 3 · registry result, not featured evidence
9.7%1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
8.7%0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
6.9%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1%1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
2.6%1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
7%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
7.3%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
4.1%1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2.5%0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2.9%1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
0%0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
8.2%2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
11.3%16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
12.9%8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.4%21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
3.9%2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
3.9%2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
3.9%2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.7%2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—j
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
1.7%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.6%4.5 mg
NCT03495102 · Phase 3
1.1%3 mg
NCT03495102 · Phase 3
0.8%1.5 mg
NCT03495102 · Phase 3
—1.5 mg
NCT01621178 · Phase 3
—0.75 mg
NCT01621178 · Phase 3
1.9%1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
0%0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
1.7%Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
—
NCT03315780 · Phase 4 · registry result, not featured evidence
—1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
0%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
1.4%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
0%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
4%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
2.3%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
4.3%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
4.2%
NCT01769378 · Phase 3 · registry result, not featured evidence
2.5%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
0.4%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
—1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
6%LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
2.6%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
1.3%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
8.3%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
—1.0 mgk
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
—0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT03819153 · Phase 3
—1.0 mg weekly
NCT02054897 · Phase 3
—0.5 mg weekly
NCT02054897 · Phase 3
—1.0 mg weekly
NCT01930188 · Phase 3 · combination
—0.5 mg weekly
NCT01930188 · Phase 3 · combination
—1.0 mg/week
NCT02128932 · Phase 3
—0.5 mg/week
NCT02128932 · Phase 3
—2.0 mg weekly
NCT03989232 · Phase 3
—1.0 mg weekly
NCT03989232 · Phase 3
—1.0 mg weekly
NCT02305381 · Phase 3
—0.5 mg weekly
NCT02305381 · Phase 3
—
NCT04126603 · Phase 4 · registry result, not featured evidence
—
NCT05786521 · Phase 4 · registry result, not featured evidence
3.8%
NCT05533632 · Phase 4 · registry result, not featured evidence
—once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
2.2%
NCT03596450 · Phase 4 · registry result, not featured evidence
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
—
NCT04560998 · Phase 3 · registry result, not featured evidence
—
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
NCT03689374 · Phase 3 · registry result, not featured evidence
—1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
—0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
—
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
—1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
—1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
0%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
0%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
—2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
—2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
40.3%j
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
5%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.2%4.5 mg
NCT03495102 · Phase 3
7.3%3 mg
NCT03495102 · Phase 3
8.7%1.5 mg
NCT03495102 · Phase 3
21.4%1.5 mg
NCT01621178 · Phase 3
25.3%0.75 mg
NCT01621178 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
1.9%1.5 mg
NCT02963766 · Phase 3
4%1.5 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
2%0.75 mg
NCT02963766 · Phase 3
2%0.75 mg
NCT02963766 · Phase 3
0%1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
0%0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
2.5%0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
5%0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
0%
NCT03315780 · Phase 4 · registry result, not featured evidence
31.9%1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
3.8%1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
3.6%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
5.6%1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
3.5%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
2.1%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
6%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
9.3%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
5.8%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
3.8%
NCT01769378 · Phase 3 · registry result, not featured evidence
2.5%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
1.6%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
1.7%1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
—LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
3.9%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
8.9%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
3.7%1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
0%1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
9.1%0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
0%Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
0%Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
0%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
33.6%1.0 mgk
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
35%0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
9.4%1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
49.6%
NCT03819153 · Phase 3
5.4%1.0 mg weekly
NCT02054897 · Phase 3
5.5%0.5 mg weekly
NCT02054897 · Phase 3
7.3%1.0 mg weekly
NCT01930188 · Phase 3 · combination
7.3%0.5 mg weekly
NCT01930188 · Phase 3 · combination
4.7%1.0 mg/week
NCT02128932 · Phase 3
6.1%0.5 mg/week
NCT02128932 · Phase 3
4.4%2.0 mg weekly
NCT03989232 · Phase 3
5.2%1.0 mg weekly
NCT03989232 · Phase 3
9.2%1.0 mg weekly
NCT02305381 · Phase 3
6.1%0.5 mg weekly
NCT02305381 · Phase 3
0%
NCT04126603 · Phase 4 · registry result, not featured evidence
0%
NCT05786521 · Phase 4 · registry result, not featured evidence
1%
NCT05533632 · Phase 4 · registry result, not featured evidence
22.5%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
6%
NCT03596450 · Phase 4 · registry result, not featured evidence
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.2%Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
5.9%INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
9.8%7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
19.7%1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
18.7%
NCT04560998 · Phase 3 · registry result, not featured evidence
6.2%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
7.4%
NCT03689374 · Phase 3 · registry result, not featured evidence
6.6%1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
6.3%0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
4.6%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
5.9%1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
4.7%1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
7.7%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
5.6%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
5%1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
7.9%0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2%1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
5.8%0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
6.7%2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
1.6%16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.3%8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.4%21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
2.6%2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
7.8%2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
6.5%2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
4.1%2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
j
nausea 14.9% (placebo 5.4%)
diarrhoea 13.5% (placebo 8.8%)
nasopharyngitis 11.4% (placebo 10.8%)
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 41 more results
nasopharyngitis 27.1%
diarrhoea 12.2%
nausea 9.4%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.5 mg
nausea 17.3%
diarrhoea 11.4%
vomiting 10.4%
NCT03495102 · Phase 3
3 mg
nausea 16.1%
diarrhoea 12.2%
vomiting 9.3%
NCT03495102 · Phase 3
1.5 mg
nausea 14.2%
diarrhoea 7.8%
vomiting 6.5%
NCT03495102 · Phase 3
1.5 mg
blood creatinine increased 38.5%
nausea 19.8%
diarrhoea 16.1%
NCT01621178 · Phase 3
0.75 mg
blood creatinine increased 37.4%
diarrhoea 15.8%
nausea 14.2%
NCT01621178 · Phase 3
1.5 mg
diarrhoea 21.2% (placebo 13.7%)
headache 15.4% (placebo 9.8%)
nausea 15.4% (placebo 7.8%)
NCT02963766 · Phase 3
1.5 mg
diarrhoea 12% (placebo 13.7%)
nausea 12% (placebo 7.8%)
abdominal pain upper 10% (placebo 7.8%)
NCT02963766 · Phase 3
0.75 mg
vomiting 17.6% (placebo 3.9%)
diarrhoea 15.7% (placebo 13.7%)
headache 13.7% (placebo 9.8%)
NCT02963766 · Phase 3
0.75 mg
headache 10.2% (placebo 9.8%)
vomiting 8.2% (placebo 3.9%)
abdominal pain 6.1% (placebo 5.9%)
NCT02963766 · Phase 3
1.5 mg
gastritis 14.3%
dyslipidaemia 9.5%
nausea 9.5%
NCT05659537 · Phase 4 · registry result, not featured evidence
0.75 mg
anaemia 21.4%
gastritis 14.3%
dyslipidaemia 7.1%
NCT05659537 · Phase 4 · registry result, not featured evidence
0.75 mg
nasopharyngitis 15.8% (placebo 30.8%)
abdominal discomfort 8.3% (placebo 12.8%)
constipation 6.7% (placebo 12.8%)
NCT02750410 · Phase 4 · registry result, not featured evidence
0.75 mg
nasopharyngitis 28.3% (placebo 30.8%)
constipation 10.8% (placebo 12.8%)
abdominal discomfort 9.2% (placebo 12.8%)
NCT02750410 · Phase 4 · registry result, not featured evidence
influenza 16.7% (placebo 0%)
decreased appetite 8.3% (placebo 0%)
diarrhoea 8.3% (placebo 8.3%)
NCT03315780 · Phase 4 · registry result, not featured evidence
1.5 mg
nausea 22.3%
diarrhoea 18.9%
covid-19 15.1%
NCT04255433 · Phase 3 · registry result, not featured evidence
1.5 mg
constipation 12.5%
diarrhoea 10.2%
pyrexia 10%
NCT04809220 · Phase 3 · registry result, not featured evidence
0.75 mg
constipation 8.7%
nasopharyngitis 8.7%
covid-19 8.2%
NCT04809220 · Phase 3 · registry result, not featured evidence
1.5 mg
decreased appetite 22.2% (placebo 4.1%)
diabetic nephropathy 13.9% (placebo 15%)
diarrhoea 13.2% (placebo 8.2%)
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
1.5 mg
nausea 14.8% (placebo 3.6%)
back pain 9.2% (placebo 7.1%)
viral upper respiratory tract infection 6.3% (placebo 7.9%)
NCT02597049 · Phase 3 · registry result, not featured evidence
0.75 mg
diarrhoea 9.9% (placebo 2.9%)
back pain 8.5% (placebo 7.1%)
viral upper respiratory tract infection 5.7% (placebo 7.9%)
NCT02597049 · Phase 3 · registry result, not featured evidence
nausea 12% (placebo 1.3%)
diarrhoea 11.3% (placebo 4%)
upper respiratory tract infection 7.3% (placebo 6.7%)
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
hyperlipidaemia 17.8%
diarrhoea 16.7%
lipase increased 10.5%
NCT01648582 · Phase 3 · registry result, not featured evidence
0.75 mg
hyperlipidaemia 19.5%
diarrhoea 10.9%
hypertension 10.9%
NCT01648582 · Phase 3 · registry result, not featured evidence
nausea 10.5% (placebo 0%)
diarrhoea 8.4% (placebo 0%)
eructation 5.9% (placebo 0%)
NCT01769378 · Phase 3 · registry result, not featured evidence
1.5 mg
diarrhoea 17.2%
hyperlipidaemia 11.1%
nausea 10.2%
NCT01644500 · Phase 3 · registry result, not featured evidence
0.75 mg
hyperlipidaemia 12.1%
diarrhoea 7.3%
lipase increased 5.6%
NCT01644500 · Phase 3 · registry result, not featured evidence
1.5 mg weekly
nausea 20.4%
diarrhoea 12%
dyspepsia 8%
NCT01624259 · Phase 3 · registry result, not featured evidence
4.5 mg
nausea 30.3% (placebo 4.9%)
diarrhoea 21.1% (placebo 11.1%)
vomiting 13.2% (placebo 4.9%)
NCT02973100 · Phase 2 · registry result, not featured evidence
3.0 mg
nausea 25.3% (placebo 4.9%)
diarrhoea 22.8% (placebo 11.1%)
decreased appetite 16.5% (placebo 1.2%)
NCT02973100 · Phase 2 · registry result, not featured evidence
1.5 mg
nausea 22.2% (placebo 4.9%)
diarrhoea 11.1% (placebo 11.1%)
vomiting 11.1% (placebo 4.9%)
NCT02973100 · Phase 2 · registry result, not featured evidence
1.5 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
blood pressure decreased 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
1.5 mg
abdominal discomfort 10% (placebo 6.3%)
decreased appetite 10% (placebo 0%)
nausea 10% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.75 mg
abdominal discomfort 9.1% (placebo 6.3%)
nausea 9.1% (placebo 0%)
vomiting 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.75 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
abdominal distension 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.5 mg
abdominal discomfort 0% (placebo 6.3%)
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.5 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
abdominal pain 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
headache 41.2%
nausea 41.2%
vomiting 35.3%
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
diarrhoea 8%
haemorrhoids 4%
injection site pain 4%
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
vomiting 11.5%
decreased appetite 7.7%
headache 7.7%
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
gastrooesophageal reflux disease 33.3%
atrioventricular block first degree 28.6%
headache 28.6%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
1.0 mgk
nausea 21.8% (placebo 7.5%)
diarrhoea 18% (placebo 11.8%)
vomiting 14.8% (placebo 5.1%)
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 42 more results
0.5 mg
diarrhoea 17.9% (placebo 11.8%)
nausea 17.3% (placebo 7.5%)
lipase increased 11.4% (placebo 8%)
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
1.0 mg
nausea 22.3%
diarrhoea 11.4%
lipase increased 10.1%
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
diabetic retinopathy 19.2% (placebo 18.4%)
covid-19 12.5% (placebo 13.9%)
NCT03819153 · Phase 3
1.0 mg weekly
nausea 23.8% (placebo 7.8%)
diarrhoea 10.8% (placebo 2.3%)
headache 6.9% (placebo 6.2%)
NCT02054897 · Phase 3
0.5 mg weekly
nausea 20.3% (placebo 7.8%)
diarrhoea 12.5% (placebo 2.3%)
headache 11.7% (placebo 6.2%)
NCT02054897 · Phase 3
1.0 mg weekly
nausea 17.6%
diarrhoea 13%
vomiting 10%
NCT01930188 · Phase 3 · combination
0.5 mg weekly
nausea 17.8%
diarrhoea 13%
nasopharyngitis 12.2%
NCT01930188 · Phase 3 · combination
1.0 mg/week
nausea 22.2%
diarrhoea 19.2%
vomiting 10.3%
NCT02128932 · Phase 3
0.5 mg/week
nausea 21.3%
diarrhoea 16.3%
nasopharyngitis 12.4%
NCT02128932 · Phase 3
2.0 mg weekly
nausea 14.4%
diarrhoea 9.4%
vomiting 7.7%
NCT03989232 · Phase 3
1.0 mg weekly
nausea 14.6%
diarrhoea 8.8%
vomiting 6.7%
NCT03989232 · Phase 3
1.0 mg weekly
nausea 16.8% (placebo 4.5%)
vomiting 11.5% (placebo 3%)
diarrhoea 6.9% (placebo 1.5%)
NCT02305381 · Phase 3
0.5 mg weekly
nausea 11.4% (placebo 4.5%)
lipase increased 9.1% (placebo 3%)
nasopharyngitis 8.3% (placebo 10.5%)
NCT02305381 · Phase 3
abdominal pain 60%
NCT05786521 · Phase 4 · registry result, not featured evidence
nausea 11.5%
diarrhea 5.8%
NCT05533632 · Phase 4 · registry result, not featured evidence
once weekly
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
nausea 19.1%
vomiting 8.5%
upper respiratory tract infection 7.4%
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
nausea 18.4%
diarrhoea 13.5%
vomiting 9.7%
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
7.2 mg
nausea 29% (placebo 11.8%)
diarrhoea 18.2% (placebo 8.8%)
vomiting 16.6% (placebo 2.9%)
NCT05649137 · Phase 3 · registry result, not featured evidence
1.0 mg
covid-19 5.6% (placebo 0%)
decreased appetite 5.6% (placebo 0%)
diabetic retinopathy 5.6% (placebo 5.7%)
NCT04865770 · Phase 3 · registry result, not featured evidence
covid-19 7.6% (placebo 5.3%)
nausea 5.6% (placebo 0.8%)
NCT04560998 · Phase 3 · registry result, not featured evidence
covid-19 14.4%
diarrhoea 12.1%
nausea 11.5%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nausea 14.8%
diarrhoea 7.4%
nasopharyngitis 6.5%
NCT03689374 · Phase 3 · registry result, not featured evidence
1.0 mg weekly
diarrhoea 16.9%
nausea 13.4%
upper respiratory tract infection 13.1%
NCT03061214 · Phase 3 · registry result, not featured evidence
0.5 mg weekly
diarrhoea 20.2%
upper respiratory tract infection 9.8%
lipase increased 7.7%
NCT03061214 · Phase 3 · registry result, not featured evidence
nausea 22.7%
diarrhoea 15.1%
vomiting 12.8%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1.0 mg
nausea 21.5%
diarrhoea 15.6%
decreased appetite 10.4%
NCT03191396 · Phase 3 · registry result, not featured evidence
1.0 mg weekly
nausea 19.3% (placebo 3.3%)
diarrhoea 11.3% (placebo 6%)
vomiting 9.3% (placebo 2%)
NCT03086330 · Phase 3 · registry result, not featured evidence
1.0 mg
nausea 21%
diarrhoea 13.7%
vomiting 10.3%
NCT02648204 · Phase 3 · registry result, not featured evidence
0.5 mg
nausea 22.3%
diarrhoea 14.3%
vomiting 10%
NCT02648204 · Phase 3 · registry result, not featured evidence
1.0 mg
nasopharyngitis 31.1%
nausea 19.1%
diarrhoea 15.8%
NCT02207374 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 33.9%
constipation 18.4%
nausea 12.1%
NCT02207374 · Phase 3 · registry result, not featured evidence
1.0 mg
nasopharyngitis 17.6%
nausea 12.7%
constipation 11.8%
NCT02254291 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 16.5%
constipation 14.6%
nausea 10.7%
NCT02254291 · Phase 3 · registry result, not featured evidence
2.0 mg
nausea 21.7% (placebo 15.3%)
vomiting 18.3% (placebo 6.8%)
diarrhoea 15% (placebo 11.9%)
NCT05486065 · Phase 2 · registry result, not featured evidence
16.0 mg
nausea 37.1% (placebo 15.3%)
vomiting 25.8% (placebo 6.8%)
diarrhoea 21% (placebo 11.9%)
NCT05486065 · Phase 2 · registry result, not featured evidence
8.0 mg
nausea 41.7% (placebo 15.3%)
diarrhoea 33.3% (placebo 11.9%)
vomiting 23.3% (placebo 6.8%)
NCT05486065 · Phase 2 · registry result, not featured evidence
21.6 mg
injection site erythema 10.2% (placebo 0%)
injection site reaction 10.2% (placebo 0%)
diarrhoea 8.5% (placebo 11.5%)
NCT05144984 · Phase 2 · registry result, not featured evidence
2.4 mg + 12.0 mg
diarrhoea 14.3% (placebo 11.5%)
constipation 9.1% (placebo 1.6%)
covid-19 7.8% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 2.4 mg
nausea 19.5% (placebo 1.6%)
diarrhoea 14.3% (placebo 11.5%)
covid-19 7.8% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 21.6 mg
diarrhoea 13% (placebo 11.5%)
nausea 13% (placebo 1.6%)
covid-19 11.7% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 7.2 mg
diarrhoea 21.6% (placebo 11.5%)
lipase increased 12.2% (placebo 3.3%)
nausea 12.2% (placebo 1.6%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe reported result categories differ.
  5. eTreatment context differs: combination versus add on.
  6. fAssessment timepoints differ: 52 weeks versus 28 weeks.
  7. gAssessment timepoints differ: 40 weeks versus 36 weeks.
  8. hTrial phases differ: Phase 4 versus Phase 3.
  9. iAssessment timepoints differ: 104 weeks versus 156 weeks.
  10. jPopulation comparability has not been reviewed for 44 of these studies.
  11. kPopulation comparability has not been reviewed for 43 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

dulaglutide

Microvascular Composite 22.2% (n=4949) vs 25.1% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 1099 Participants as posted
HF Hospitalization or Urgent Visit 4.3% (n=4949) vs 4.6% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 213 Participants as posted
Unstable Angina Hospitalization 1.8% (n=4949) vs 1.6% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 88 Participants as posted
HbA1c Less Than or Equal to 6.5 51.1% (n=178) vs 24% (n=179) Insulin Glargine @ 26wk
responder rate · % of participants
HbA1c <=6.5%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 71.3% (n=178) vs 45.8% (n=179) Insulin Glargine @ 26wk
responder rate · % of participants
HbA1c <7%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
FBG -34.3 vs -37.8 Insulin Glargine mg @ 26wk
absolute change · mg
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Serum Glucose Change mg/dL -52.3 mg @ 36wk4.5 mg
absolute change · mg
No placebo or comparator arm
NCT03495102 · Phase 3
show 4 more results
-47.9 mg @ 36wk3 mg
NCT03495102 · Phase 3
-44.2 mg @ 36wk1.5 mg
NCT03495102 · Phase 3
-42.4 mg @ 52wk1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-33.1 mg @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 8 78.3% (n=152) vs 75.3% (n=182) Insulin Glargine @ 26wk1.5 mg
responder rate · % of participants
NCT01621178 · Phase 3
show 3 more results
69.1% (n=152) vs 70.3% (n=182) Insulin Glargine @ 52wk1.5 mg
NCT01621178 · Phase 3
72.6% (n=164) vs 75.3% (n=182) Insulin Glargine @ 26wk0.75 mg
NCT01621178 · Phase 3
69.5% (n=164) vs 70.3% (n=182) Insulin Glargine @ 52wk0.75 mg
NCT01621178 · Phase 3
SMBG 8-point Change mg/dL -33.7 vs -37.6 Insulin Glargine mg @ 26wk1.5 mg
absolute change · mg
NCT01621178 · Phase 3
show 1 more result
-31.7 vs -37.6 Insulin Glargine mg @ 26wk0.75 mg
NCT01621178 · Phase 3
Fasting Glucose Change mg/dL 23.1 vs -19.1 Insulin Glargine mg @ 26wk1.5 mg
absolute change · mg
NCT01621178 · Phase 3
show 2 more results
17.7 vs -19.1 Insulin Glargine mg @ 26wk0.75 mg
NCT01621178 · Phase 3
-44.63 vs -27.9 placebo mg @ 28wk
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
Daily Insulin Dose 18.12 vs 16.64 Insulin Glargine per day @ 26wk1.5 mg
absolute change · per day
NCT01621178 · Phase 3
show 4 more results
20.05 vs 16.84 Insulin Glargine per day @ 52wk1.5 mg
NCT01621178 · Phase 3
26.16 vs 16.64 Insulin Glargine per day @ 26wk0.75 mg
NCT01621178 · Phase 3
27.46 vs 16.84 Insulin Glargine per day @ 52wk0.75 mg
NCT01621178 · Phase 3
-1.1 vs -0.3 placebo per day @ 16wk
NCT02750410 · Phase 4 · registry result, not featured evidence
Serum Creatinine Change mg/dL 0.04 vs 0.1 Insulin Glargine mg/dL @ 26wk1.5 mg
absolute change · mg/dL
NCT01621178 · Phase 3
show 3 more results
0.07 vs 0.12 Insulin Glargine mg/dL @ 52wk1.5 mg
NCT01621178 · Phase 3
0.02 vs 0.1 Insulin Glargine mg/dL @ 26wk0.75 mg
NCT01621178 · Phase 3
0.04 vs 0.12 Insulin Glargine mg/dL @ 52wk0.75 mg
NCT01621178 · Phase 3

+ 54 further endpoints in the CSV export.

Semaglutide (Ozempic)

HbA1c 6.5 or Less 47% (n=404) vs 22% (n=405) Exenatide ER @ 56wk1.0 mg
event count · % of participants
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 190 Participants as posted
Chronic Dialysis 4.9% (n=1767) vs 5.7% (n=1766) placebo
event rate · % of participants
NCT03819153 · Phase 3 · converted to % from 87 Participants as posted
Renal Death 0.3% (n=1767) vs 0.3% (n=1766) placebo
event count · % of participants
NCT03819153 · Phase 3 · converted to % from 5 Participants as posted
UACR 0.6 vs 0.89 placebo ratio @ 104wk
ratio to baseline · ratio
NCT03819153 · Phase 3
Non-fatal MI 2.9% (n=1767) vs 3.6% (n=1766) placebo
event count · % of participants
NCT03819153 · Phase 3 · converted to % from 52 Participants as posted
MALE 0.9% (n=1767) vs 1.6% (n=1766) placebo
event rate · % of participants
NCT03819153 · Phase 3 · converted to % from 16 Participants as posted
Acute Limb Ischemia 0.1% (n=1767) vs 0.2% (n=1766) placebo @ 234wk
event rate · % of participants
Acute limb ischaemia hospitalization
NCT03819153 · Phase 3 · converted to % from 1 Participants as posted
Chronic Limb Ischemia Hospitalization 0.9% (n=1767) vs 1.4% (n=1766) placebo @ 234wk
event count · % of participants
Chronic limb ischaemia hospitalization
NCT03819153 · Phase 3 · converted to % from 16 Participants as posted
SBP -5.17 vs -1.68 Insulin Glargine mmHg @ 30wk1.0 mg/week
absolute change · mmHg
NCT02128932 · Phase 3
show 13 more results
-4.3 vs -3.7 Liraglutide mmHg @ 30wk1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
-4.3 vs 1.1 placebo mmHg @ 30wk1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
-4.65 vs -1.68 Insulin Glargine mmHg @ 30wk0.5 mg/week
NCT02128932 · Phase 3
-8 vs -3 placebo mmHg @ 72wk7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
-3 vs 0 placebo mmHg @ 34wk21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
-6 vs 0 placebo mmHg @ 34wk2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
-10 vs 0 placebo mmHg @ 34wk2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
-9 vs 0 placebo mmHg @ 34wk2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
-13 vs 0 placebo mmHg @ 34wk2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
-3.9 vs -1.4 placebo mmHg @ 104wk
NCT03819153 · Phase 3
-2.3 vs -1.8 Standard of Care mmHg @ 52wk
NCT03596450 · Phase 4 · registry result, not featured evidence
-3 vs -2.8 Standard of Care mmHg @ 104wk
NCT03596450 · Phase 4 · registry result, not featured evidence
-4 vs -1 placebo mmHg @ 52wk
NCT04560998 · Phase 3 · registry result, not featured evidence
DBP -0.98 vs -1.44 Insulin Glargine mmHg @ 30wk1.0 mg/week
absolute change · mmHg
NCT02128932 · Phase 3
show 7 more results
-1.5 vs -1.3 Liraglutide mmHg @ 30wk1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
-0.1 vs -0.1 placebo mmHg @ 30wk1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
-1.38 vs -1.44 Insulin Glargine mmHg @ 30wk0.5 mg/week
NCT02128932 · Phase 3
-3 vs -3 placebo mmHg @ 72wk7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.8 placebo mmHg @ 104wk
NCT03819153 · Phase 3
-1.6 vs -0.9 Standard of Care mmHg @ 52wk
NCT03596450 · Phase 4 · registry result, not featured evidence
-1.9 vs -1.4 Standard of Care mmHg @ 104wk
NCT03596450 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 60% (n=130) vs 13.2% (n=129) placebo @ 30wk1.0 mg weekly
responder rate · % of participants
NCT02054897 · Phase 3
show 10 more results
61.1% (n=131) vs 4.5% (n=133) placebo @ 30wk1.0 mg weekly
NCT02305381 · Phase 3
70.6% (n=238) vs 31.6% (n=250) Sitagliptin @ 30wk1.0 mg weekly
Yes
NCT03061214 · Phase 3 · registry result, not featured evidence
58.5% (n=290) vs 24.8% (n=287) Liraglutide @ 30wk1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
60% (n=120) vs 3.9% (n=127) placebo @ 30wk1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
66.7% (n=300) vs 34.1% (n=299) Dulaglutide @ 40wk1.0 mg
Yes
NCT02648204 · Phase 3 · registry result, not featured evidence
59.4% (n=128) vs 13.2% (n=129) placebo @ 30wk0.5 mg weekly
Yes
NCT02054897 · Phase 3
40.9% (n=132) vs 4.5% (n=133) placebo @ 30wk0.5 mg weekly
NCT02305381 · Phase 3
60.4% (n=235) vs 31.6% (n=250) Sitagliptin @ 30wk0.5 mg weekly
Yes
NCT03061214 · Phase 3 · registry result, not featured evidence
49.2% (n=301) vs 34.1% (n=299) Dulaglutide @ 40wk0.5 mg
Yes
NCT02648204 · Phase 3 · registry result, not featured evidence
62.1% (n=293) vs 26.8% (n=313) Canagliflozin @ 52wk
Yes
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
SBP -5.61 vs -2.29 Sitagliptin mmHg @ 56wk1.0 mg weekly
absolute change · mmHg
Systolic blood pressure
NCT01930188 · Phase 3 · combination
show 1 more result
-5.07 vs -2.29 Sitagliptin mmHg @ 56wk0.5 mg weekly
Systolic blood pressure
NCT01930188 · Phase 3 · combination

+ 108 further endpoints in the CSV export.

Atherosclerotic Cardiovascular Disease

Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline

dulaglutide · Trulicity

Marketed by Eli Lilly

Approved in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT01394952 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).

Next expected readout: December 2030 · NCT07282041 (registry estimate)

Reported efficacy

Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 (met)

Result source: NCT01394952

Semaglutide (Ozempic)

Marketed by Novo Nordisk

Approved in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT01720446 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).

Next expected readout: July 2028 · NCT07073053 (registry estimate)

Reported efficacy

Change in Maximum Walking Distance on a Constant Load Treadmill Test (Baseline (week 0), end of treatment (week 52)): Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill (met)

Result source: NCT04560998

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdulaglutideSemaglutide (Ozempic)
LDL-C, % change—Trial running · NCT07282041—Not reported
Non-HDL-C, % change—Trial running · NCT07282041—Not reported
ApoB, % change—Trial running · NCT07282041—Not reported
Lp(a), % change—Trial running · NCT07282041—Not reported
3-point MACE (% with event)—Trial running · NCT07282041—Not reported

LDL-C, % change

dulaglutide
—Trial running · NCT07282041
Semaglutide (Ozempic)
—Not reported

Non-HDL-C, % change

dulaglutide
—Trial running · NCT07282041
Semaglutide (Ozempic)
—Not reported

ApoB, % change

dulaglutide
—Trial running · NCT07282041
Semaglutide (Ozempic)
—Not reported

Lp(a), % change

dulaglutide
—Trial running · NCT07282041
Semaglutide (Ozempic)
—Not reported

3-point MACE (% with event)

dulaglutide
—Trial running · NCT07282041
Semaglutide (Ozempic)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

dulaglutide
Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 NCT01394952 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. dulaglutide: 0 of 4 rows · Semaglutide (Ozempic): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSemaglutide (Ozempic)
Dropout rate
7.6%a
NCT04560998 · Phase 3
Discontinued due to AEs
—a
NCT04560998 · Phase 3
Serious AEs
18.7%a
NCT04560998 · Phase 3
Most frequent reported AEs
a
covid-19 7.6% (placebo 5.3%)
nausea 5.6% (placebo 0.8%)
NCT04560998 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Semaglutide (Ozempic)

Max Walking Distance 1.21 vs 1.08 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
show 1 more result
1.16 vs 1.1 placebo ratio @ 57wk
NCT04560998 · Phase 3
VascuQoL-6 2 vs 1 placebo score @ 52wk
absolute change · score
NCT04560998 · Phase 3
Pain-free Walking Distance 1.21 vs 1.1 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
show 1 more result
1.18 vs 1.1 placebo ratio @ 57wk
NCT04560998 · Phase 3
HbA1c -0.8% (n=304) vs 0.2% (n=311) placebo @ 52wk
absolute change · percentage points
NCT04560998 · Phase 3
Weight -5.2 vs -1.2 placebo kg @ 52wk
absolute change · kg
NCT04560998 · Phase 3
SBP -4 vs -1 placebo mmHg @ 52wk
absolute change · mmHg
NCT04560998 · Phase 3
Total Cholesterol 0.96 vs 1 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
LDL Cholesterol 0.99 vs 1.03 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
HDL Cholesterol 1.04 vs 0.99 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
Triglyceride 0.8 vs 0.95 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
ABI 1.06 vs 1.02 placebo ratio @ 52wk
absolute change · ratio
NCT04560998 · Phase 3
TBI 1.07 vs 1.04 placebo ratio @ 52wk
absolute change · ratio
NCT04560998 · Phase 3

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · Semaglutide (Ozempic)'s landscape